Protalix BioTherapeutics, Inc. (PLX)

Instructure Holdings Revenue

Protalix BioTherapeutics had revenue of $10.11M in the quarter ending March 31, 2025, with 169.82% growth. This brings the company's revenue in the last twelve months to $59.76M, up 0.18% year-over-year. In the year 2024, Protalix BioTherapeutics had annual revenue of $53.40M, down -18.47%.

• Revenue (ttm): $59.76M
• Revenue Growth: +0.18%
• P/S Ratio: 1.78
• Revenue / Employee: $280,582
• Employees: 213
• Market Cap: 115.43M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	53.40M	-12.10M	-18.47%
Dec 31, 2023	65.49M	17.86M	37.48%
Dec 31, 2022	47.64M	9.29M	24.22%
Dec 31, 2021	38.35M	-24.55M	-39.03%
Dec 31, 2020	62.90M	8.21M	15.00%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.